After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ORGO falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Organogenesis Holdings Inc is $662.04M. A total of 1.25 million shares were traded on the day, compared to an average of 1.78M shares.
In the most recent transaction, Driscoll Michael Joseph bought 25,000 shares of ORGO for 5.08 per share on Mar 04 ’25. In a previous transaction on Mar 04 ’25, Driscoll Michael Joseph sold 25,000 shares at 5.10 per share. ORGO shares that Director owns now total 166,879.
Among the insiders who sold shares, Gillheeney Gary S. disposed of 55,615 shares on Dec 13 ’24 at a per-share price of $3.36. This resulted in the President and CEO holding 3,044,779 shares of ORGO after the transaction. In another insider transaction, Gillheeney Gary S. sold 5,585 shares at $3.49 per share on Dec 16 ’24. Company shares held by the President and CEO now total 3,039,194.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ORGO has a high of $6.71 and a low of $2.16.
As of this writing, ORGO has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.03.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.09, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.50.
